Inactive Instrument

ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Biotechnology & Medical Research

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference

November 02, 2023 at 04:38 pm EDT

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for November 15, 2023 at 9:30 am GMT / 4:30 am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102139307/en/

Latest news about ImmunoGen, Inc.

AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	Feb. 13	MT
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	Feb. 12	CI
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	Feb. 12	MT
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12	MT
AbbVie Acquires ImmunoGen for $31.26 per Share	Feb. 12	MT
AbbVie: acquisition of ImmunoGen finalized	Feb. 12	CF
Immunogen, Inc. Announces Board Changes	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	Feb. 11	CI
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	Feb. 11	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Biotechnology Index	Feb. 08	CI
ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing	Feb. 07	MT
ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing	Feb. 07	MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks	Feb. 02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing	Jan. 19	MT
Drugmakers kick off industry conference with two cancer deals	Jan. 08	RE
J&J to buy cancer therapy developer Ambrx for $2 bln	Jan. 08	RE
2023 highlights of the stock market year	Dec. 21
BioMarin settles with Elliott, adds 3 independent directors	Dec. 20	RE
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	Dec. 10	CI
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup	Dec. 08	DJ

Chart ImmunoGen, Inc.

Duration

Period

More charts

Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+46.73%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research